46
Participants
Start Date
March 29, 2018
Primary Completion Date
September 30, 2020
Study Completion Date
September 30, 2020
CBT-1®
"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Mayo Clinic, Jacksonville
RECRUITING
Sarcoma Oncology Research Center, Santa Monica
RECRUITING
Seattle Cancer Care Alliance, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
Lead Sponsor
CBA Research
INDUSTRY